Free Trial

More results...

Filter by Content types
Regulatory databases
Regulatory reports
Market reports
News analysis
Filter by Geography
Africa
Asia
Australasia
Europe
United Kingdom
North America
United States
South America

Alerts LATEST ALERTS

  • Ireland Ruling parties disagree on proposal to decriminalise personal drug use ...
  • Brazil Up to 0.3% THC in plants authorised for medical, pharmaceutical, industrial use ...
  • Australia Parliamentary committee makes suggestions for cannabis law in NSW ...
  • Australia Greens announce Parliament will vote on cannabis legalisation this month ...
  • Texas - United States Bills introduced in Senate and House on medical cannabis expansion ...
  • Texas - United States House bill introduced to regulate hemp production and require research permit ...
  • Texas - United States House bills introduced on legalising recreational cannabis ...
  • Lithuania - Ukraine Cannabis conference focuses on fibre hemp, addressing challenges, restrictions ...
  • Czech Republic Criminal law reform approved, will relax some cannabis-related laws ...
  • New Zealand First sublingual THC/CBD spray meets Medicinal Cannabis Agency quality standard ...
  • Poland Motion for cannabis decriminalisation presented to prime minister ...
  • Belgium Health Belgium updates notified herbal products for smoking list ...
View all
News analysis

Growing investor interest sparks more funding for psychedelic clinical trials

Written by || 10th December 2021 || News analysis | Companies | GeographiesEngland Europe North America United Kingdom United States

The potential of psychedelics to treat a range of mental health conditions continues to attract increasing levels of funding for clinical trials as firms work towards bringing them into mainstream medical use.

Boston-based Preclinical neuroscience company Delix Therapeutics recently closed an initial Series A round of funding, in which it raised $70m for clinical trials of its psychoplastogen compounds.

Read full article

Download the full news analysis

"*" indicates required fields

Name*
*
This field is for validation purposes and should be left unchanged.

I'm already a subscriber

Login

Author default picture

Lorraine Mullaney

Senior writer
Lorraine is responsible for writing news analysis and assisting with copy-editing. Lorraine is a copywriter and editor who has written and edited words for a wide range of audiences, from local community newspapers to consumer magazines and trade websites.

Our Key Benefits

The global cannabis market is in an opaque regulatory environment that requires professionals to be on top of industry developments to make informed decisions and optimise their strategy.

CannIntelligence provides organisations with leading market and regulatory data analysis to anticipate and understand market developments globally and the impact of regulatory changes to the business.

  • Stay informed of any legal and market change in the sector that impacts your organisation
  • Maximise resources by getting market and legal data analysis daily in one place
  • Make smart decisions by understanding how the regulatory and market landscape evolves
  • Anticipate risks in your decisions by monitoring regulatory changes that impact your organization

Thanks for getting in touch with us

Please leave your enquiry and we will get back to you within 24 hours

"*" indicates required fields

Name*
*
This field is for validation purposes and should be left unchanged.

Sign up to our newsletter

Stay up-to-date with key market trends and regulatory news and receive complimentary data on a regular basis.

"*" indicates required fields

Name*
*
This field is for validation purposes and should be left unchanged.